Theravance Biopharma/$TBPH
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Theravance Biopharma
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
- Ticker
- $TBPH
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 90
- Headquarters
- South San Francisco, United States
- Website
- www.theravance.com
TBPH Metrics
BasicAdvanced
$884M
16.30
$1.05
0.25
-
Price and volume
Market cap
$884M
Beta
0.25
52-week high
$21.03
52-week low
$13.08
Average daily volume
914K
Financial strength
Current ratio
13.543
Quick ratio
13.263
Long term debt to equity
0.096
Total debt to equity
0.096
Interest coverage (TTM)
8.27%
Profitability
EBITDA (TTM)
11.102
Gross margin (TTM)
75.06%
Net profit margin (TTM)
51.58%
Operating margin (TTM)
9.16%
Effective tax rate (TTM)
8.67%
Revenue per employee (TTM)
$1,160,000
Management effectiveness
Return on assets (TTM)
1.33%
Return on equity (TTM)
20.91%
Valuation
Price to earnings (TTM)
16.296
Price to revenue (TTM)
8.34
Price to book
3.05
Price to tangible book (TTM)
3.05
Price to free cash flow (TTM)
16.19
Free cash flow yield (TTM)
6.18%
Free cash flow per share (TTM)
1.052
Growth
Revenue change (TTM)
35.11%
Earnings per share change (TTM)
308.45%
3-year revenue growth (CAGR)
26.72%
10-year revenue growth (CAGR)
10.49%
3-year earnings per share growth (CAGR)
-57.10%
10-year earnings per share growth (CAGR)
-14.04%
What the Analysts think about TBPH
Analyst ratings (Buy, Hold, Sell) for Theravance Biopharma stock.
Analyst projections of the future price of Theravance Biopharma stock.
TBPH Financial Performance
Revenues and expenses
TBPH Earnings Performance
Company profitability
Upcoming events
No upcoming events
TBPH News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.